Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharmaceuticals, Inc. - Common Stock
(NQ:
ARWR
)
20.51
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
August 14, 2025
H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.
Via
Stocktwits
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
August 14, 2025
Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company.
Via
Investor's Business Daily
Topics
Death
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial
August 14, 2025
Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.
Via
Stocktwits
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
August 13, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For August 7, 2025
August 07, 2025
Via
Benzinga
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement
July 23, 2025
Via
Stocktwits
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript
August 07, 2025
Via
The Motley Fool
Topics
Earnings
Arrowhead (ARWR) Q3 Revenue Drops 41%
August 07, 2025
Via
The Motley Fool
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss
August 07, 2025
Arrowhead Pharmaceuticals reported mixed Q3 2025 results, beating revenue estimates but missing on EPS. Stock fell 5.3% as higher R&D costs widened losses. Key pipeline updates include plozasiran NDA...
Via
Chartmill
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
August 07, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
August 01, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?
July 29, 2025
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,...
Via
Benzinga
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
July 28, 2025
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.
Via
Benzinga
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
July 28, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
July 25, 2025
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.
Via
Benzinga
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
July 25, 2025
Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.
Via
Investor's Business Daily
Topics
Death
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 24, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
July 23, 2025
Via
Benzinga
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
July 23, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review
July 22, 2025
Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.
Via
Benzinga
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
July 21, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
July 08, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
June 23, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'
June 04, 2025
Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of "Mad Money Lightning Round."
Via
Benzinga
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
June 02, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
May 29, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Archer Aviation Posts Narrower-Than-Expected Loss, Joins Microvast, Intuitive Machines And Other Big Stocks Moving Higher On Tuesday
May 13, 2025
Via
Benzinga
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
May 13, 2025
Via
Benzinga
Which stocks are moving after the closing bell on Monday?
May 12, 2025
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
May 12, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.